{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"113"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Count of participants who died during the study","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"NUMBER","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"42 months","title":"Number of Participants Who Died","type":"PRIMARY","unitOfMeasure":"participants"}